Total weight loss at 48-68 weeks on the combination is difficult to predict without clinical trial data, but based on individual compound data (retatrutide at 24-28.7% and the additive benefit seen with CagriSema), a reasonable estimate for the combination is 25-35% total body weight reduction in high responders
If doses other than these are required, the rhinal tube delivery system may be used
The Kinetex C 18 (100 4.6 mm, 2.6 m 100 A) column (Phenomenex, Torrance, USA) was used for chromatographic separation using 50 % water (with the addition of 0.04 % formic acid) as solvent A and 50 % methanol as solvent B
There is no TGA-registered BPC-157 product for therapeutic use in Australia, and as of June 2024 BPC-157 is a Schedule 4 (prescription-only) substance, meaning any legal supply must come through a doctors prescription via a compounding pharmacy
A supplier who ships with proper cold chain packaging is signaling that they understand the product they sell
It's the same concept
